En effet ak en vue (Bolero/KBC ce matin).
BRUSSELS, Feb 5 (Reuters) - Belgian pharmaceutical supplies
group Fagron said on Friday it was in talks with
investors over a capital increase of 220 million euros ($246.3
million) and would not pay a dividend for the 2015 financial
year.
The announcement follows a turbulent year for the company,
in which its long-serving chief executive stepped down and the
group held talks to sell itself to another company which
eventually failed.
The company has been given until the end of March by its
financing banks to find a solution.
Fagron said the capital increase would take the shape of a
private capital injection in combination with a public share
issue.
In 2015 core profit, adjusted for one-off items, fell some
10 percent to 106.5 million euros.
The weakening of the Brazilian real, where Fagron has a lot
of business, and changes to rules on reimbursement in the United
States both had a negative impact.
Fagron took an impairment of 225.6 million euros at the end
of 2015 related to the profitability of pharmaceutical raw
materials and reduced non-sterile compounding in the United
States.
($1 = 0.8933 euros)
Bien à vous,
demat
Dernière modification par demat (05-02-2016 09:51:26)
